Navigation Links
Trio of studies support use of PET/CT scans as prostate cancer staging tool
Date:10/21/2011

ROCHESTER, Minn. -- Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer. The results of three studies, released today during a meeting of the North Central Section of the American Urological Association (http://www.ncsaua.org/default.aspx), validate findings in Europe and expand the potential use of C-11 choline PET scans.

One study found that C-11 choline PET/CT scans can be used as a staging tool rather than multiple x-rays, but is not necessarily better. Two additional studies support the favorable claims made in recent medical literature about the use of PET scans to evaluate patients with recurrent prostate cancer. These findings are important because distinguishing localized disease recurrence from systemic recurrence is a vital step in optimizing treatment following primary treatment failure.

"Taken together, the three studies presented today represent an important validation of the C-11 choline PET/CT scan as a staging tool for patients with prostate cancer," says R. Jeffrey Karnes, M.D. (http://www.mayoclinic.org/bio/12463493.html), senior author of all three papers. "We believe the use of these scans can improve the staging and treatment of this common form of cancer, while potentially reducing the cost of delivering the best possible care."

Positron emission tomography is an imaging test that uses a small amount of radioactive material to reveal how tissues and organs are functioning. A C-11 choline PET scan involves the injection into a vein of a small amount of C-11 choline, a radioactive form of the vitamin choline. Clinicians then use a scanner and computer to make detailed pictures of areas where the C-11 choline collects. Since cancer cells take up more C-11 choline than normal cells, the pictures can be used to find cancer in the body.

Summary of the Three Studies

"Initial Staging for High-Risk Prostate Cancer: Is there a Role for C-11 Choline PET Scan?" The findings suggest that C11-choline PET is an accurate diagnostic tool when used as the initial staging modality prior to definitive treatment and could potentially eliminate the need for CT and/or bone scans.

"Detection of Consolidated Disease Recurrences of Prostate Cancer by C-11 Choline PET Scan: Results Confirmed by Surgical Resection" This study found that a C-11 choline PET scan is an accurate diagnostic tool for detecting localized disease recurrences that, in select cases, are suitable for salvage surgical resection.

"Operational Characteristics of C-11 Choline PET Scan for Prostate Cancer Patients with Biochemical Recurrence Following Initial Treatment" The operational performance of C11-choline PET for evaluating patients with recurrent prostate cancer supports the favorable claims regarding this technology. The use of C-11-choline PET substantially enhances the rate of prostate cancer lesion detection by approximately 30% beyond what can be garnered using conventional imaging technologies.


'/>"/>
Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Hospital Programs to Reduce Antibiotic Resistance Working: Studies
2. Start HIV Drug Treatment Early in Patients With TB: Studies
3. Researchers review studies on CCSVI-MS link
4. Clemson researchers using interactive vision tool for driving studies
5. FDA Focuses on Silicone Breast Implant Safety Studies
6. SHSU studies GPS monitoring of Arizona sex offenders
7. Studies shed light on hand hygiene knowledge and infection risk in hospitals and elementary schools
8. WU studies obesity, cancer link with $9.2 million grant
9. Minority participants crucial to effective aging studies
10. Studies examine impact of media use among youth, recommend preventative measures
11. Related studies point to the illusion of the artificial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... Battle Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... abuse, joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table ... held in honor of the city’s history as home to some of the world’s ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: